NYSE:AMPE

Ampio Pharmaceuticals Stock News

etoro logo Buy AMPE
*Your capital is at risk
$0.183
+0 (+0%)
At Close: Jun 03, 2026
ENGLEWOOD, Colo., Nov. 23, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call with its CEO and

Ampio Pharmaceuticals Inc. (AMEX: AMPE): Should Value Hunters Buy It?

04:00pm, Tuesday, 23'rd Nov 2021 Stocks Register
The trading price of Ampio Pharmaceuticals Inc. (AMEX:AMPE) closed lower on Monday, November 22, closing at $1.14, -8.06% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
In the last trading session, 1.15 million shares of the Ampio Pharmaceuticals Inc. (AMEX:AMPE) were traded, and its beta was 1.57. Most recently the companys share price was $1.24, and it changed around $0.09 or 7.83% from the last close, which brings the market valuation of the company to $232.40M. AMPE currently trades at a Its Easy To Bet On Ampio Pharmaceuticals Inc. (AMEX: AMPE) For Economic Progress Over The Impending Months Read More »
ENGLEWOOD, Colo., Nov. 22, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced that Mike Macaluso is taking a one-year medical leave of
LPL Financial LLC grew its stake in shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) by 73.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,564 shares of the specialty pharmaceutical companys stock after purchasing an additional 45,914 shares during the quarter. LPL Financial []
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $1.50 target price on the specialty pharmaceutical companys stock. Zacks Investment Researchs price target suggests a potential upside of 30.43% from the companys previous []

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Ampio (AMPE)

03:00pm, Thursday, 18'th Nov 2021 Zacks Investment Research
The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r
The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r
JPMorgan Chase & Co. purchased a new position in shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 73,026 shares of the specialty pharmaceutical companys stock, valued at approximately $122,000. Other large investors have also added to or []
Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript
ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflam
ENGLEWOOD, Colo., Sept. 21, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent infl
Investing in penny stocks right now? Check these three small caps out for your watchlist The post Best Penny Stocks For Retail Traders to Buy?
Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE